FINCH THERAPEUTICS GROUP INC (FNCH) Stock Price, Forecast & Analysis
USA - NASDAQ:FNCH - US31773D2009 - Common Stock
FNCH Key Statistics, Chart & Performance
The current stock price of FNCH is 1.8 USD. In the past month the price decreased by -22.41%. In the past year, price decreased by -78.26%.
FNCH Latest News, Press Relases and Analysis
FNCH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.22 | 387.57B | ||
| AMGN | AMGEN INC | 14.57 | 171.54B | ||
| GILD | GILEAD SCIENCES INC | 14.74 | 149.75B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.49 | 104.57B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.33 | 68.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 846.82 | 56.61B | ||
| INSM | INSMED INC | N/A | 38.75B | ||
| NTRA | NATERA INC | N/A | 26.80B | ||
| BIIB | BIOGEN INC | 9.18 | 22.53B | ||
| INCY | INCYTE CORP | 16.29 | 20.42B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.93 | 20.21B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.12 | 14.98B |
Related stock screener links
About FNCH
Company Profile
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. The company is headquartered in Boston, Massachusetts and currently employs 18 full-time employees. The company went IPO on 2021-03-19. The company is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. The company has an intellectual property estate, including more than 70 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The Company’s assets include CP101, an orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection (CDI), with positive clinical data from a Phase II randomized, placebo-controlled trial and a Phase II open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Additionally, it has also developed a biorepository of strains and samples.
Company Info
FINCH THERAPEUTICS GROUP INC
75 State Street, Suite 100
Boston MASSACHUSETTS US
Employees: 18
Phone: 16172296499
FINCH THERAPEUTICS GROUP INC / FNCH FAQ
What does FNCH do?
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. The company is headquartered in Boston, Massachusetts and currently employs 18 full-time employees. The company went IPO on 2021-03-19. The company is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. The company has an intellectual property estate, including more than 70 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The Company’s assets include CP101, an orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection (CDI), with positive clinical data from a Phase II randomized, placebo-controlled trial and a Phase II open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Additionally, it has also developed a biorepository of strains and samples.
Can you provide the latest stock price for FINCH THERAPEUTICS GROUP INC?
The current stock price of FNCH is 1.8 USD. The price decreased by -9.09% in the last trading session.
Does FNCH stock pay dividends?
FNCH does not pay a dividend.
What is the ChartMill rating of FINCH THERAPEUTICS GROUP INC stock?
FNCH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is FINCH THERAPEUTICS GROUP INC (FNCH) stock traded?
FNCH stock is listed on the Nasdaq exchange.
What sector and industry does FINCH THERAPEUTICS GROUP INC belong to?
FINCH THERAPEUTICS GROUP INC (FNCH) operates in the Health Care sector and the Biotechnology industry.
Can you provide the short interest for FNCH stock?
The outstanding short interest for FINCH THERAPEUTICS GROUP INC (FNCH) is 0.01% of its float.
FNCH Technical Analysis
FNCH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FNCH. The financial health of FNCH is average, but there are quite some concerns on its profitability.
FNCH Financial Highlights
Over the last trailing twelve months FNCH reported a non-GAAP Earnings per Share(EPS) of -10.15. The EPS increased by 89.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.51% | ||
| ROE | -85.55% | ||
| Debt/Equity | 0 |
FNCH Forecast & Estimates
7 analysts have analysed FNCH and the average price target is 91.8 USD. This implies a price increase of 5000% is expected in the next year compared to the current price of 1.8.
For the next year, analysts expect an EPS growth of 45.96% and a revenue growth -100% for FNCH